Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.33 |
| ▸ | BMPR2 | Q13873 | 3/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23947980 | 0.84 | HCAR1 (0.35) | KDR | |
| SCHEMBL26306206 | 0.83 | — | — | |
| SCHEMBL23948320 | 0.82 | EGLN1 (0.32) | — | |
| SCHEMBL23948323 | 0.82 | MAPK1 (0.38) | ACVR1MET | |
| SCHEMBL23948322 | 0.82 | MELK (0.40) | KDR | |
| SCHEMBL23948444 | 0.82 | KDR (0.31) | FLT3BMPR1BKDRBMPR1AACVRL1 | |
| SCHEMBL23947973 | 0.81 | — | — | |
| SCHEMBL26306189 | 0.81 | PIK3CD (0.31) | — | |
| SCHEMBL26306213 | 0.81 | KDM5B (0.32) | — | |
| SCHEMBL23948328 | 0.80 | ABL1 (0.38) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2021211882-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | LTK, FRK, LCK | FLT3 13/4885BMPR1B 1940/4885KDR 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.